id.DRIVE COVID-19 Vaccine Effectiveness Study
Research type
Research Study
Full title
Brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe A contribution of id.DRIVE, a public-private partnership to estimate brand-specific COVID-19 vaccine effectiveness in Europe.
IRAS ID
343229
Contact name
Lydia Joanne Finney
Contact email
Sponsor organisation
P95
Clinicaltrials.gov Identifier
42328, EUPAS
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This protocol details a non-interventional study to estimate the effectiveness of COVID-19 vaccines against COVID-19 related hospitalisations through the id.DRIVE partnership. Studying the effectiveness against COVID-19 hospitalisations is prioritised as accurate and timely information on how well the different COVID-19 vaccines protect and remain protective over time against hospitalisations is essential to successfully manage the pandemic. Considering the rarity of COVID-19 hospitalisations, clinical trials are not well suited to study this outcome and complementary real-world studies are required. This protocol describes a multi-centre, hospital-based, case-control study with test-negative controls (test-negative case-control design, TNCC). Data will be collected through a wide network of hospitals located in several European countries. A hospital-based case-control study is an efficient design for studying rare outcomes, potentially allowing for detailed medical information and additional data collection directly from the patient or healthcare provider.
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
24/PR/1102
Date of REC Opinion
7 Mar 2025
REC opinion
Further Information Favourable Opinion